Tango Therapeutics, Inc. (TNGX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$22.49

From 52W high−28.48%

Volume1.87M

Market cap$3.97B

P/E (TTM)—

P/S (TTM)73.7x

Div yield—

Key dataOct 19, 2026

Open

$22.49

From 52W high

−28.48%

Volume

1.87M

Market cap

$3.97B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−24.5x

P/E (TTM)

—

RSI (14)

48.5

MomentumView details →

1D Return

+6.76%

YTD Return

+160.69%

SummaryUpdated Jun 1, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in September 2020 through a special purpose acquisition company (SPAC) merger. Tango focuses on discovering and developing targeted cancer therapies using a precision medicine approach called synthetic lethality, where drugs are designed to selectively kill cancer cells with specific genetic vulnerabilities while sparing healthy cells.

Ask drillr about Tango Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−24.5x

EV/Sales

55.5x

P/S (TTM)

73.7x

P/B (TTM)

3.9x

ProfitabilityView details →

Gross Margin

98.25%

Net Margin

−229.92%

EBITDA Margin

−226.46%

ROE (TTM)

−12.08%

ROA (TTM)

−11.52%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

+121.47%

EPS YoY

+35.61%

FCF YoY

+3.28%

Revenue CAGR 3Y

+35.89%

EPS CAGR 3Y

+26.89%

EBITDA YoY

+18.74%

MomentumView details →

1D Return

+6.76%

YTD Return

+160.69%

1Y Return

+152.43%

RSI (14)

48.5

vs 50D SMA

−3.28%

vs 200D SMA

+6.32%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

50.82x

Quick Ratio

50.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.37

EPS Surprise

−16.64%

Beats (12Q)

3/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

298.05%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

53.81M

Net Income (TTM)

−123.72M

Op. CF (TTM)

−143.90M

Next earningsNov 3, 2026 →

Latest newsMore news →

Tango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.74d ago

Similar companies

Arcutis Biotherapeutics, Inc.ARQT 华恒生物688639.SH Ocumension Therapeutics01477.HK Jacobio Pharmaceuticals Group Co., Ltd.01167.HK AbCellera Biologics Inc.ABCL Catalyst Pharmaceuticals, Inc.CPRX Find similar companies →

Latest newsMore news →

Tango Therapeutics reported Q2 2026 financial results with zero revenue, a net loss of $55.3 million, and diluted EPS of -$0.37, while highlighting a 92% objective response rate for vopimetostat plus daraxonrasib and a 90% six-month progression-free survival rate.70d ago Tango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.74d ago